Envafolimab for gallbladder and bile duct cancers that spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies envafolimab, an anti-cancer medicine that helps the immune system fight cancer, in people with gallbladder or bile duct cancer that is advanced or has spread. It aims to see how well the treatment works and what side effects people experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of gallbladder cancer or bile duct cancer (cholangiocarcinoma).
- You should not have had chemotherapy for advanced disease already, unless it was for earlier treatment and the cancer came back more than 6 months after finishing.
- Your liver and kidneys need to work well enough for treatment, based on specific blood test limits.
- Your overall health should be good (ECOG 0 or 1) and you should have cancer areas that can be measured on scans.
- You must be able to sign the informed consent form and understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs—envafolimab (an immunotherapy), chemotherapy, and simvastatin (a cholesterol medicine)—for people with advanced bile duct or gallbladder cancer that hasn't been treated yet or came back after surgery. The goal is to see if adding simvastatin helps the treatment work better.
This trial tests a combination of treatments for people with bile duct or gallbladder cancer that cannot be removed by surgery. It uses a procedure to burn the tumor (radiofrequency ablation) along with two drugs: one that boosts your immune system and one that targets blood vessels feeding the cancer.
This trial tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) for biliary tract cancer that can be removed by surgery. The goal is to prevent cancer from coming back after surgery.
This trial tests a new two-drug combination (sacituzumab tirumotecan and envafolimab) for people with advanced bile duct or gallbladder cancer that has already been treated with immunotherapy plus chemotherapy. It aims to see if these drugs can shrink or control the cancer.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.